New tool helps patients and doctors choose psoriasis treatments together
NCT ID NCT03737045
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to create and test a decision aid for people with psoriasis or psoriatic arthritis who are starting or switching treatments. Researchers worked with 37 patients and their doctors to design a tool that supports shared decision-making. The goal was to help patients feel more informed and involved in choosing their therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
37 people
The number who actually took part.
- Started
-
Dec 2018
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age 18 years or older 2. Diagnosis of psoriasis (as confirmed by dermatologist) or psoriatic arthritis (as confirmed by rheumatologist) 3. Treated at Penn In addition to the above, for the observation and implementation phases of the study: 4. Initiation of a new psoriasis or psoriatic arthritis treatment * Biosimilars that have been approved by the FDA and available on the US market will similarly be eligible for participation * Patients may be taking other traditional DMARDs. * A washout period is not required. Exclusion Criteria: 1. Unable to give informed consent 2. Youth, under the age of 18 years 3. Patients without psoriasis or psoriatic arthritis 4. Not being treated at a Penn clinic In addition to the above, for the observation and implementation phases of the study: 5. Not starting or switching to a new medication
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Psoriasis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital at the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Job-Focused rehab program keep arthritis patients employed?
- Can a Once-Daily moisturizer help psoriasis skin? patients put it to the test
- Can an oral drug calm psoriatic arthritis? phase 3 trial puts deucravacitinib to the test
- Can a fruit acid in tiny carriers rival steroid creams for psoriasis?
- Vitamin B3 supplement put to the test against psoriasis inflammation
- Do rheumatic diseases quietly damage the Eye's oil glands?